Erik L. Ridley[email protected]Editor's NoteWeek in Review: New ACP screening guidelines draw ire | FDA AI ruling | ARRS 2026 coverageControversial new breast cancer screening guidelines from the ACP and ARRS 2026 coverage generated the most interest among AuntMinnie members this week.April 17, 2026MRIMRI highlights worse muscle health from ultra-processed foodsA study has found that ultra-processed food consumption is tied to higher thigh-muscle fat infiltration on MRI.April 14, 2026Womens ImagingPrivate equity firms set to acquire Hologic in $18B dealIn a blockbuster deal valued at up to $18.3 billion, women's health firm Hologic has agreed to be acquired by Blackstone and TPG.October 21, 2025Editor's NoteWeek in Review: AI industry payments | Catching more breast cancers | NEJM pediatric CT studyArticles on breast cancer screening and AI industry payments were the most highly viewed on AuntMinnie last week.September 27, 2025Editor's NoteWeek in Review: The rise of theranostics | Imaging and blood cancer risk | Fewer false-positive recallsPart 6 of "The rise of theranostics" series and research tying imaging with blood cancer risk were top stories last week.September 20, 2025Editor's NoteAuntMinnie.com AI InsiderThis edition of AuntMinnie's AI Insider features a wide range of content for AI enthusiasts, including a variety of video interviews and in-depth conference coverage.June 11, 2025AIAI quantifies brain changes from post-CAR-T cell therapy complicationResearchers recently explored the use of a deep-learning algorithm to quantify ICANS neurotoxicity following CAR T-cell therapy.June 11, 2025Editor's NoteWeek in Review: AI and radiologist liability | PET and alcohol abuse | SalaryScanThe most popular stories this week on AuntMinnie featured legal liability issues with radiology AI and PET imaging of alcohol use disorder.June 7, 2025AIClairity deploys AI for breast cancer risk predictionClairity believes that its new AI software can deliver improvements over traditional breast cancer risk-prediction models.June 6, 2025Nuclear MedicineRadium-223 safety confirmed in long-term studyAt ASCO 2025, researchers shared data on the long-term safety of Ra-223 treatments for metastatic castration-resistant prostate cancer.June 2, 2025Page 1 of 18Next PageTop StoriesCTAI algorithm shines in spotting early pancreatic cancerThe findings could help shift diagnosis of PDA from late-stage terminal disease to early-stage treatable disease.MRIFunctional MRI predicts CTD-ILD progression better than standard testsMolecular ImagingPET improves treatment planning for pituitary tumorsAIReplacing radiologists doesn’t remove risk -- it moves it to patientsSponsor ContentTurning Innovation into Everyday Efficiency
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=167&q=70&w=250)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
